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Rate Variation in Early Growth Restricted Fetuses 
 
Introduction 
In human pregnancy, a single course of antenatal corticosteroids reduces the occurrence of respiratory 
distress syndrome and other complications following preterm birth [1]. However, antenatal 
betamethasone treatment has been reported to induce transient effects on fetal behavior, including a 
decrease in fetal heart rate and reduced short term fetal heart rate variation without decelerations, 
observed up to 4 days after administration [2]. Doppler studies in small cohorts of human pregnancies 
complicated by fetal growth restriction (FGR) have observed a temporary decrease in the pulsatility 
index (PI) of the umbilical artery (UA), the reappearance of end-diastolic flow in this vessel, and/or 
a decrease in the ductus venosus PI (DVPIV) [3-5].  Other studies did not observe such changes [6,7]. 
Therefore, there is ongoing discussion as to whether such effects of betamethasone represent ominous 
clinical signs of worsening of the fetal condition or simply transient effects with no significant 
sequelae for the developing infant [2].  This discussion is further compounded by the current paucity 
of data derived from large human cohorts, particularly those involving pregnancies with FGR.           
The recent Trial of Umbilical and Fetal Flow in Europe (TRUFFLE) multi-centre study on the 
management of severe early onset FGR has reported a more favorable neurological outcome among 
those fetuses who were delivered based on both Doppler assessment of the ductus venosus (DV) and 
cardiotocography (CTG) [8].  In this context, the possible effects of glucocorticoids on changes in 
DVPIV and fetal CTG short term variability (CTG-STV) might have played a significant role that 
would benefit from clarification.  
The aim of this study was to investigate the effects of antenatal betamethasone administration on fetal 
CTG-STV, DV Doppler waveform and umbilico-cerebral ratio (UC ratio, calculated as the ratio 
between the pulsatility index of the umbilical artery and the pulsatility index of the middle cerebral 
artery) in the TRUFFLE cohort. 
 
Methods 
We conducted a post-hoc analysis of data from the TRUFFLE study, a prospective, multicentre, 
randomized management trial that took place in 20 European tertiary care centres in five countries 
[8]. Eligible participants for the TRUFFLE trial were women over 18 years of age, with a singleton 
pregnancy at 26+ 0 to 31+ 6 weeks of gestation diagnosed with early isolated FGR, defined as fetal 
abdominal circumference below the 10th percentile and umbilical artery Doppler PI above the 95th 
percentile. Details about inclusion and exclusion criteria have been previously reported [8]. The 
intervention was delivery of the fetus according to the criteria of the randomization group, determined 
by CTG indices of reduced short-term variation (CTG-STV; CTG-STV<3.5 ms at <29 weeks of 
gestation or CTG-STV <4 ms at ≥29 weeks of gestation ), early abnormalities of the DV waveform 
(DVPIV ≥95th centile) or late DV changes (absent or negative A-wave). In cases where 
corticosteroids had been given to accelerate fetal lung maturation, no decision regarding delivery was 
made on the grounds of reduced STV from 24 h to 72 h after the first intramuscular injection. 
Following 32+ 0 weeks, the timing of delivery was according to local management protocol and the 
decision to deliver was based on local criteria as DV waveforms were no longer taken into 
consideration [8]. In all groups, delivery could be undertaken based on maternal indications, such as 
severe pre-eclampsia. The study protocol was approved by the institutional ethics committee, and 
patients provided written informed consent. For the current post-hoc study we selected women who 
had been treated with corticosteroids for improving fetal maturity because it was expected that 
delivery was imminent due to deterioration of the fetal condition in association with FGR. The timing 
of maternal prophylactic steroid administration was according to local protocols. Two doses of 
intramuscular 12 mg betamethasone were given, the second 12–24 h after the first. Repeated doses 
of steroids were never administered. To qualify for this post hoc study women should have a CTG-
STV recorded within 48 hours before the first corticosteroid administration and at least 2 CTG-STV 
recorded in the following week. CTG-STV values were categorized as pre-corticosteroids and in 24-
hour periods after corticosteroids up to 10 days. Because it was expected that in this group of women 
with a pregnancy complicated by severe FGR the fetal wellbeing would deteriorate at a certain 
moment, necessitating delivery, and that at that moment CTG-STV would be low, and DVPIV and 
UC ratio would be high, as a result of fetal condition, in order to avoid possible bias, we excluded 
from the current analysis CTG-STV and Doppler values recorded within 48 hours from delivery. The 
Oxford Sonicaid 8002 system or an equivalent Dawes-Redman software based algorithm were used 
for STV calculation. The recordings were at least 45 min in duration. CTG-STV measurements were 
not necessarily performed at the same time intervals following betamethasone administration nor at 
the same time during the day. For all the fetuses included, repeated measurements between the first 
betamethasone dose (day +1) and 10 days after (+10) were considered. According to the study 
protocol UA pulsatility index (PI), middle cerebral artery (MCA) PI, DVPIV and CTG-STV were 
assessed in each fetus before randomization. We evaluated, for each different measurement in each 
fetus, between +1 and + 10, the relative change from the last recording within 48 hours before the 
first dose of betamethasone (basal value) for CTG-STV (i.e. CTG-STVn-CTG-STV0/CTG-STV0), 
DVPIV, and UC ratio.  After randomization the TRUFFLE protocol recommended measurement of 
UA PI, MCA PI, CTG-STV and DVPIV, (if randomized to the DV-groups) to be performed at least 
once weekly, but assessment could be more frequent according to local policies. Median and 
interquartile ranges (IQR) were used for descriptive statistics. The Kruskal–Wallis test was used to 
test if a difference in the medians of CTG-STV and Doppler indices was detectable for 10 days after 
steroid administration. Multiple comparisons were subsequently performed using Dunn's test with 
Bonferroni correction. Based on literature we expected a small increase of STV during the first day 
and a decrease on day 2 or 3 [9]. Multilevel analysis was performed to verify such a pattern and to 
evaluate the course of CTG-STV, DVPIV, and UC ratio longitudinally. We assessed whether there 
was a significant time effect on the Doppler and CTG-STV values for 10 days from steroids 
administration and whether changes of these biophysical parameters were significantly affected by 
other clinical variables. Multilevel analysis allows for the dependency of measurements and can be 
used if there are missing data and/or when measurements have been made at different time points. 
Repeat Doppler and CTG assessment in the same fetus at different gestational ages belong to the first 
level and the different fetuses in the study belong to the second level [10].  For further analysis of 
CTG-STV and Doppler indices, a mixed model based on clinical predictors was constructed, 
removing items from the initial model in a stepwise manner when the t-test p value was > 0.15. The 
variables evaluated in the models were: the ratio between the estimated fetal weight (EFW) and the 
50th centile for EFW at that gestational age (EFW p50 ratio) , fetal gender, presence of fetal heart 
rate decelerations at cardiotocography; CTG-STV; DVPIV; umbilical artery end diastolic flow 
(UAEDF, present versus absent or reverse); and days from delivery. The dependent variables were 
the individual Doppler indices and CTG-STV (the dependent variable was of course removed from 
the variables tested in the model). Since the main aim of the study was to evaluate the longitudinal 
course of fetal Doppler waveforms and CTG-STV after corticosteroids administration, we never 
removed from the model the time variable expressed as the number of days elapsed from the first 
dose of corticosteroids. Since the decision to administer steroids is usually made on the basis of 
worsening fetal or maternal conditions in view of a decision to terminate the pregnancy, we performed 
an analysis forcing the steroid-to-delivery interval (expressed in days) into the model. The Wald test 
was used to assess significance of parameter estimates. Values of p < 0.05 were considered 
statistically significant. Statistical analysis was performed with Stata 13.1 (StataCorp. 2013. Stata: 
Release 13. Statistical Software. College Station, TX: StataCorp LP) [11].  
 
Results 
The TRUFFLE trial [8] included 503 women, 476 (95%) of these received corticosteroids to improve 
fetal maturity. Most of these women (n=361; 72%) did not have a computerized CTG within 48 hours 
before the first corticosteroid administration recorded in the study database, because corticosteroids 
had been given before referral from a secondary care center, or before study inclusion was considered. 
A total of 115 women (23 %) qualified for this secondary analysis (Fig. 1, Tab. 1). Tab. 2 shows the 
number of observations and the change from baseline (median, IQR), recorded in each day of the 
study interval for CTG-STV and Doppler parameters.  An increase of CTG-STV from basal value 
was found on day +1 (p=0.019), after the first dose of corticosteroids (Tab. 2, Fig. 2). DVPIV was 
not significantly different from basal in any of the 10 days following the first dose of betamethasone 
(p=0.167), although a slight, non-significant decrease could be observed on day +1 (Tab. 3, Fig. 3). 
During the 10-day period of observation there were no significant changes from baseline in the UC 
ratio (Tab. 4, Fig. 4).  
Multilevel analysis applying the steroid-to-delivery interval into the model demonstrated that after 
stepwise removal of less significant predictors, the time elapsed from antenatal administration of 
betamethasone was associated with a decrease in CTG-STV in the following 10 days (p=0.045; Fig. 
2, Tab. S1). In addition, the time elapsed from the first dose of steroids was associated with an increase 
in the DVPIV (p=0.001, Tab. S2) and in the UC ratio (p < 0.001, Tab. S3). However, all the regression 




In a cohort of early FGR fetuses with abnormal umbilical artery Doppler, we showed that antenatal 
administration of betamethasone is associated with a clinically detectable increase in CTG-STV the 
first day after the first dose of steroids followed by a small decrease in CTG-STV afterwards. 
Multilevel analysis further revealed that although the time elapsed from steroid administration was 
statistically significantly associated with CTG-STV, the DVPIV and the UC ratio relative changes, 
the magnitude of these associations was clinically irrelevant. The change we observed in CTG-STV, 
a short increase after the first dose of betamethasone, followed by a small decrease in STV in the days 
afterwards was similar to the effect described by Mulder et al. [13]. The current data show that the 
effect of betamethasone in FGR fetuses is similar to what seen in pregnancies with preterm premature 
rupture of the membranes or premature labour. This strongly suggests that the change in CTG-STV 
is independent of placental function.  
Previous research has described a possible effect of antenatal maternal administration of 
corticosteroids on fetal heart rate variables. A transient increase in fetal arterial blood pressure, 
induced by glucocorticoids [14], will increase the vagal drive to the fetal heart by recruiting 
baroreceptor afferent fiber discharge as part of a baroreflex [15].  The withdrawal of sympathetic 
outflow will lower the low frequency/high frequency ratio of the fetal heart rate power spectrum, 
thereby in keeping with transient depressive effects of glucocorticoids on fetal heart rate variation 
[9]. Clinical studies observing an effect of steroids on CTG-STV, however, were never performed on 
a large population of well-defined early severe FGR fetuses such as the TRUFFLE cohort [2]. In 
FGR, high placental vascular resistance leads to an increase in fetal cardiac afterload, myocardial 
dysfunction and ductus venosus dilatation, all possibly associated with CTG-STV decrease and 
DVPIV increase [16]. It is possible that the severe progressive chronic hypoxia characterizing 
TRUFFLE fetuses might limit further compensatory responses to steroids. 
With regards to short-term changes in Doppler indices, our findings are in agreement with an earlier 
study in 57 early FGR fetuses [7] and with a recent prospective study reporting no change in DVPIV 
in the preterm FGR fetus following maternal treatment with betamethasone [17]. However, in the 
latter study this was observed in FGR fetuses with a mean gestational age of 34 weeks, significantly 
later than in our cohort. During the 10-day period of observation the course of CTG-STV, the DVPIV 
and the UC ratio are consistent with a progressive deterioration of the fetal condition due to worsening 
chronic fetal hypoxemia [16] rather than the use of betamethasone. In agreement with some previous 
studies both the UC ratio and DVPIV changes shortly after maternal betamethasone administration 
were not clinically significant [7,18,19]. Our observations did not confirm previous reports of a 
DVPIV reduction after betamethasone [5]. We highlight that a progressive deterioration of the fetal 
condition, due to chronic fetal hypoxia, is likely to be the main determinant of longitudinal CTG-
STV and Doppler changes in early FGR fetuses [16] even after betamethasone exposure. Chronic 
fetal hypoxia leads to a circulatory compromise that accounts for increased ductus venosus shunting 
[20], myocardial dysfunction and fetal acidosis [21,22]. This can be documented as a progressive 
increase in DVPIV, manifested initially as a deepening and, ultimately, reversal of the A-wave [23]. 
Deferring delivery until absent or reverse flow during the A-wave, unless delivery is mandated earlier 
by the CTG safety net criteria, compared with delivery based only on CTG-STV, is a safe 
management strategy with regard to intact survival without impairment at 2 years of age, corrected 
for prematurity [8,24-27]. According to our data, any CTG-STV decrease [8,28] within 72 hours from 
the first dose of steroids might be interpreted as a sign of fetal deterioration due to progressing chronic 
fetal hypoxia. At the same time, the occurrence of spontaneous FHR decelerations, included in the 
TRUFFLE study as a safety net criterion to deliver the fetus, does not seem to be induced by 
corticosteroids [2] and remains therefore important for fetal surveillance after steroid administration, 
just as the assessment of the ductus venosus.  
The main strength of our analysis is that effects of antenatal steroids on Doppler indices and CTG-
STV were evaluated in a large population of early severe FGR fetuses followed up longitudinally 
until delivery. We analysed the UC ratio rather than the cerebroplacental ratio (CPR), as we 
previously demonstrated that the former allows for a better discrimination in the abnormal range [29]. 
A limitation is that evaluation of the effects of betamethasone on fetal Doppler and CTG-STV was 
not the aim of the TRUFFLE study [8].  Therefore, the number of Doppler and CTG-STV 
measurements per day is relatively small, moreover Doppler and CTG-STV measurements were not 
necessarily performed at the same time intervals following betamethasone administration nor at the 
same time during the day; however we can assume that such intervals varied randomly. Transient 
reductions in STV and fetal movements following betamethasone are not found in the morning, most 
likely since betamethasone abolishes diurnal rhythms, i.e. increases in these variables that normally 
occur during the course of the day [30].   
 
In conclusion, we demonstrate that in early FGR fetuses betamethasone administration is not 
associated with a decrease in CTG-STV after adjusting for confounders. The data available at the 
inception of the TRUFFLE trial [8], although not specific for an early FGR population, suggested a 
short term effect of steroids on CTG-STV [2]. Therefore, according to the original study protocol no 
decision regarding delivery was to be made on the grounds of reduced CTG-STV from 24 h to 72 h 
after the first dose of corticosteroids. The current study suggests that, given the lack of clinically 
significant effect of betamethasone on CTG-STV in early FGR, CTG-STV assessment remains valid 
even following steroid administration. Therefore, delivery for fetal indication should be considered 
if the CTG-STV falls below the safety net criteria of the TRUFFLE protocol, spontaneous repeated 
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Table 1. Characteristics of the TRUFFLE Fetuses included in the post hoc analysis compared 
to those of TRUFFLE fetuses not included. 
 TRUFFLE Fetuses 
included in the post 
hoc analysis (n=115) 
TRUFFLE fetuses not 
included in the  post hoc 
analysis (n=388) 
P 
Gestational age at 
randomization, weeks  
28.9 (27.7 to 30.0) 29.3 (27.9 to 30.3) 0.09 
Gestational age at the 1st dose 
of glucocorticoids 
29.0 (28.0 to 30.7) 28.6 (27.1 to 29.7) 0.00 
Gestational age at delivery, 
weeks  
30.7 (29.1 to 32.6) 30.6 (29.1 to 32.0) 0.46 
EFW at inclusion 825 (677 to 1017) 876 (708 to 1047) 0.20 
EFW p50 ratio at inclusion 0.66 ( 0.59 to  0.72) 0.65 (0.58 to 0.71) 0.47 
Randomization to delivery 
interval, days  
11 (4 to 18) 7 (3 to 17) 0.01 
Day of the 1st dose of 
glucocorticoids to delivery 
interval, days 
7 (3 to 16) 12 (5 to 24) 0.00 
UA  PI at randomization 1.8 (1.6 to 2.2) 1.9 (1.7 to 2.2) 0.44 
UA  PI at at the 1st dose of 
glucocorticoids  
1.9 (1.7 to 2.2) --- --- 
MCA PI at randomization  1.5 (1.3 to 1.7) 1.4 (1.2 to 1.7) 0.23 
MCA  PI at the 1st dose of 
glucocorticoids  
1.5 (1.2 to 1.8) --- --- 
DVPIV at randomization 0.60 (0.47 to 0.70) 0.58 (0.49 to 0.70) 0.88 
DVPIV  at the 1st dose of 
glucocorticoids  
0.57 (0.46 to 0.70) --- --- 
CTG-STV at randomization, 
ms 
6.5 (5.0 to 8.4) 6.2 (5.0 to 7.6) 0.43 
CTG-STV  at the 1st dose of 
glucocorticoids, ms 
6.3 (5.0 to 8.3) --- --- 
Fetuses with UA ARED at 
randomization 
38% 43% 0.45 
Fetuses with UA ARED at the 
1st dose of glucocorticoids  
46 % --- --- 
Fetuses with UA ARED within 
1 week before delivery 
61% 55% 0.29 
Male fetuses 56 (49%) 196 (50%) 
0.75 
Female fetuses 
59 (51%) 192 (50%) 
0.75 
Birthweight, g 970 (800 to 1170) 980 (792 to 1179) 0.98 
Birthweigth p50 ratio 0.58 (0.53 to 0.64) 0.59 (0.52 to 0.66) 0.63 
 
Median and in parenthesis interquartile range (IQR) are shown for continuous variables. P values 
are calculated by Mann-Whitney of Fisher exact test 
Abbreviations: CTG-STV, cardiotocography short-term variation; DVPIV, ductus venosus 
pulsatility index; EFW p50 ratio, ratio between the estimated fetal weight (EFW) and the 50th 
centile of the estimated fetal weight at the correspondent gestation; MCA PI, middle cerebral artery 
pulsatility index; UA PI umbilical artery pulsatility index; UA ARED umbilical artery absent or 
reverse end diastolic flow.
Table 2. Number of observations recorded and deliveries in each day of the study interval for 
CTG-STV. 
Days from the 
1st dose of 
glucocorticoids 
CTG-STV Number of pregnancies 





102/115 0 113 2 
+1 50/81 23% * 
( -2% to 42%) 74 7 
+2 55/89 8%  
(-11% to 29%) 77 12 
+3 56/86 -5%  
(-23% to 16%) 74 
12 
+4 42/62 0%  
(-19% to 25%) 
53 
9 
+5 42/59 -13%  
(-20% to 16%) 56 3 
+6 41/60 -12%  
(-28% to 4%) 50 10 
+7 28/45 -11%  
(-31% to 12%) 
41 
4 
+8 32/45 -7%  
(-19% to 13%) 38 7 
+9 29/41 -15%  
(-29% to -3%) 35 6 
+10 31/37 -5%  
(-17% to 5%) 
34 3 
Abbreviations: cardiotocography short-term variation (CTG-STV), interquartile range (IQR), number 
(n). Measurements taken within 48 hours before delivery were excluded#.  Values significantly 
different from before corticosteroids were marked with *. The number of observations recorded and 
the number of fetuses delivered in each day of the study interval is shown for CTG-STV. 
Measurements were not necessarily taken on each day for all ongoing pregnancies, moreover 
measurements taken within 48 hours before delivery were excluded.  
Table 3. Number of observations recorded and deliveries in each day of the study interval for 
DV. 
Days from the 1st dose of 
glucocorticoids 



















Before corticosteroids 61/64 0 64 0 
+1 15/24 -28%  
(-46% to 13%) 
24 0 
+2 20/30 -3% 
 (-11% to 9%) 
25 5 
+3 19/33 -5%  
(-33% to 18%) 
30 3 
+4 12/20 -7%  
(-31% to 21%) 
18 2 
+5 15/24 -9% 
 (5% to 28%) 
23 1 
+6 13/19 4%  
(-14% to 22%) 
18 1 
+7 13/22 3% 
 (-7% to 25%) 
21 1 
+8 9/16 2%  
(-2% to 5%) 
13 3 
+9 8/13 7%  
(-9% to 23%) 
12 1 
+10 14/20 7%  
(0% to 41%) 
18 2 
Abbreviations: ductus venosus pulsatility index (DVPIV). Measurements taken within 48 hours 
before delivery were excluded# 
The number of observations recorded and the number of fetuses delivered in each day of the study 
interval is shown for DVPIV. Measurements were not necessarily taken on each day for all ongoing 
pregnancies, moreover measurements taken within 48 hours before delivery were excluded.  
 
Table 4. Number of observations recorded and deliveries in each day of the study interval for 
UC ratio. 
Days from the 1st dose of 
glucocorticoids 



















Before corticosteroids 83/93 0 93 0 
+1 19/34 -5%  
(-20% to 5%) 
34 0 
+2 21/36 -2%  
(-30% to 11%) 
30 6 
+3 22/30 4%  
(-24% to 23%) 
29 1 
+4 16/25 -2%  
(-17% to 28%) 
22 3 
+5 15/25 -7%  
(-23% to 25%) 
23 2 
+6 14/20 22%  
(-21% to 44%) 
17 3 
+7 13/21 9%  
(-10% to 31%) 
21 0 
+8 10/20 11%  
(-0.5% to 28%) 
15 5 
+9 13/17 32%  
(0.5% to 43%) 
16 1 
+10 14/21 20%  
(-0.1% to 28%) 
19 2 
Abbreviations: Umbilical cerebral pulsatility index ratio (UC). Measurements taken within 48 hours 
before delivery were excluded# 
The number of observations recorded and the number of fetuses delivered in each day of the study 
interval is shown for UC ratio. Measurements were not necessarily taken on each day for all ongoing 
pregnancies, moreover measurements taken within 48 hours before delivery were excluded.  
 
  
Figure 1. Study design and population. The population of this post hoc analysis were 115 women 
who received antenatal glucocorticoids for respiratory distress syndrome prophylaxis after being 
















Table S1. Summary of multilevel stepwise regression for variables 
predicting CTG-STV relative change from the day of the first dose 
of betamethasone. Measurements taken within 48 hours before delivery 
were excluded. 
  
CTG-STV relative change from day 0 





























LEVEL 1 0 .03286  
(0.00384) 
LEVEL 2 
(fetuses) 0.01908  
(0.00548) 
Observations N 218 
Fetuses N 83 
+ p<0.15, * p<0.05, ** p<0.01, *** p<0.001 
Coeff: regression coefficient; DVPIV: ductus venosus pulsatility 
index; EFWp50 ratio: ratio between the estimated fetal weight (EFW) 
and the 50th centile of the estimated fetal weight at the 
correspondent gestation;  Gender (0,male ; 1,female); SE: standard 
error; UA EDF: umbilical artery end diastolic flow (present, 
absent/reverse.  
 
Table S2. Summary of multilevel stepwise regression for variables 
predicting DVPIV relative change from the day of the first dose of 
betamethasone. Measurements taken within 48 hours before delivery 
were excluded. 
 
DV PIV relative change from day 0 
















































































Observations N  180 180 180 
Fetuses N  69 69 69 
 
+ p<0.15, * p<0.05, ** p<0.01, *** p<0.001 
CTG-STV: cardiotocography short-term variation; EFWp50 ratio: ratio 
between the estimated fetal weight (EFW) and the 50th centile of the 
estimated fetal weight at the correspondent gestation;  Gender 
(0,male ; 1,female);; UA EDF: umbilical artery end diastolic flow 
(present, absent/reverse).  
 
Table S3. Summary of multilevel stepwise regression for variables 
predicting UC ratio relative change from the day of the first dose 
of betamethasone. Measurements taken within 48 hours before 
delivery were excluded. 
 
UC ratio relative change from day 0 
















    
    













EFWp50 ratio 0.00199  
( 0.00260) 
  
Gender 0 .03773 
(0.04646) 
  























Observations N  167 227  
Fetuses N  65 83  
+ p<0.15, * p<0.05, ** p<0.01, *** p<0.001 
Coeff: regression coefficient; CTG-STV: cardiotocography short-term 
variation; DVPIV: ductus venosus pulsatility index; EFWp50 ratio: 
ratio between the estimated fetal weight (EFW) and the 50th centile 
of the estimated fetal weight at the correspondent gestation. 
 
 
